JP2022534846A5 - - Google Patents

Info

Publication number
JP2022534846A5
JP2022534846A5 JP2021561906A JP2021561906A JP2022534846A5 JP 2022534846 A5 JP2022534846 A5 JP 2022534846A5 JP 2021561906 A JP2021561906 A JP 2021561906A JP 2021561906 A JP2021561906 A JP 2021561906A JP 2022534846 A5 JP2022534846 A5 JP 2022534846A5
Authority
JP
Japan
Prior art keywords
polypeptide
tmmp
polypeptides
amino acid
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534846A (ja
JP7762068B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034939 external-priority patent/WO2020243315A1/en
Publication of JP2022534846A publication Critical patent/JP2022534846A/ja
Publication of JP2022534846A5 publication Critical patent/JP2022534846A5/ja
Priority to JP2025070050A priority Critical patent/JP2025118689A/ja
Application granted granted Critical
Publication of JP7762068B2 publication Critical patent/JP7762068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561906A 2019-05-29 2020-05-28 多量体ｔ細胞調節性ポリペプチド及びその使用方法 Active JP7762068B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025070050A JP2025118689A (ja) 2019-05-29 2025-04-22 多量体ｔ細胞調節性ポリペプチド及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962854200P 2019-05-29 2019-05-29
US62/854,200 2019-05-29
US201962872048P 2019-07-09 2019-07-09
US62/872,048 2019-07-09
US201962901538P 2019-09-17 2019-09-17
US62/901,538 2019-09-17
PCT/US2020/034939 WO2020243315A1 (en) 2019-05-29 2020-05-28 Multimeric t-cell modulatory polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025070050A Division JP2025118689A (ja) 2019-05-29 2025-04-22 多量体ｔ細胞調節性ポリペプチド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022534846A JP2022534846A (ja) 2022-08-04
JP2022534846A5 true JP2022534846A5 (enExample) 2023-05-23
JP7762068B2 JP7762068B2 (ja) 2025-10-29

Family

ID=73552689

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561906A Active JP7762068B2 (ja) 2019-05-29 2020-05-28 多量体ｔ細胞調節性ポリペプチド及びその使用方法
JP2025070050A Withdrawn JP2025118689A (ja) 2019-05-29 2025-04-22 多量体ｔ細胞調節性ポリペプチド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025070050A Withdrawn JP2025118689A (ja) 2019-05-29 2025-04-22 多量体ｔ細胞調節性ポリペプチド及びその使用方法

Country Status (10)

Country Link
US (1) US20220017596A1 (enExample)
EP (1) EP3976084A4 (enExample)
JP (2) JP7762068B2 (enExample)
KR (1) KR20220015382A (enExample)
CN (2) CN118852456A (enExample)
AU (1) AU2020282736B2 (enExample)
CA (1) CA3137463A1 (enExample)
IL (1) IL287192A (enExample)
MX (1) MX2021014476A (enExample)
WO (1) WO2020243315A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
MX2021007479A (es) * 2018-12-19 2021-09-23 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
WO2021081232A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. Modified cytotoxic t cells and methods of use thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
AU2022238389A1 (en) * 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
WO2023097188A1 (en) * 2021-11-24 2023-06-01 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
MX2024007473A (es) * 2021-12-14 2024-09-10 Cdr Life Ag Activador del linfocito t dirigido al mhc doble.
JP2025515575A (ja) * 2022-04-14 2025-05-20 キュー バイオファーマ， インコーポレイテッド Ｔ細胞エンゲージングポリペプチドおよびその使用方法
CN115838432B (zh) * 2022-07-08 2023-12-08 浙江大学 一种靶向调控抗原特异性t细胞的融合蛋白及应用
CN116063463B (zh) * 2022-08-12 2025-08-01 辽宁成大生物股份有限公司 抗rHPV68 L1蛋白CD68单克隆抗体、rHPV68型蛋白抗原的检测试剂盒
EP4577223A2 (en) * 2022-08-26 2025-07-02 Beam Therapeutics Inc. Modified allogeneic cells and methods and compositions for the preparation thereof
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
KR101442209B1 (ko) * 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 융합 단백질, 이의 용도 및 이의 제조방법
CA2785907A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
WO2014012082A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
WO2014096015A1 (en) * 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
JP6594855B2 (ja) * 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2015195531A2 (en) 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
WO2017151818A2 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3014466A1 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) * 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) * 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
US11407806B2 (en) * 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
WO2022119958A1 (en) * 2020-12-02 2022-06-09 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022534846A5 (enExample)
JP2022548472A5 (enExample)
JP2020514375A5 (enExample)
JP2020533273A5 (enExample)
CN110325205B (zh) T细胞调节性多聚体多肽及其使用方法
JP2022515331A5 (enExample)
KR20220066075A (ko) T-세포 조절 폴리펩타이드 및 이의 사용 방법
JP7282760B2 (ja) バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
JP2020511949A5 (enExample)
WO2021255138A1 (en) Immune activating fc domain binding molecules
US20240067700A1 (en) T-cell modulatory polypeptides and methods of use thereof
JP2022536581A5 (enExample)
JP2023500574A5 (enExample)
JP2018525006A5 (enExample)
US20260053855A1 (en) Modified Cytotoxic T Cells and Methods of Use Thereof
CN113286621A (zh) 多聚体t细胞调节多肽及其使用方法
JP2023512452A (ja) Ｂｃｍａ指向性細胞免疫療法組成物および方法
JP2023500573A5 (enExample)
JP7742354B2 (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
US20240067699A1 (en) T-cell modulatory polypeptides and methods of use thereof
JP2024541334A5 (enExample)
US20250326813A1 (en) Engineered interleukin-2 receptor beta reduced-binding agonist
WO2015167948A1 (en) Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
JP2024517658A5 (enExample)
US20260109958A1 (en) T-Cell Modulatory Polypeptides and Methods of Use Thereof